Cohance Lifesciences is trading -3.58% lower at Rs 425.65 as compared to its last closing price. Cohance Lifesciences has been trading in the price range of 444.80 & 422.80. Cohance Lifesciences has given -16.39% in this year & -12.18% in the last 5 days. Cohance Lifesciences has TTM P/E ratio 108.11 as compared to the sector P/E of 22.69.There are 8 analysts who have initiated coverage on Cohance Lifesciences. There are 2 analysts who have given it a strong buy rating & 3 analysts have given it a buy rating. 1 analysts have given the stock a sell rating.The company posted a net profit of 74.08 Crores in its last quarter.Listed peers of Cohance Lifesciences include Cipla (-2.52%), Torrent Pharmaceuticals (0.35%), Dr Reddy's Laboratories (-0.91%).The Mutual Fund holding in Cohance Lifesciences was at 16.49% in 30 Sep 2025. The MF holding has decreased from the last quarter. The FII holding in Cohance Lifesciences was at 6.51% in 30 Sep 2025. The FII holding has decreased from the last quarter.
Updated on Jan 18, 2026, 04:45 PM UTC
|
| ||||
|
| ||||
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Cipla | Bearish | 1,398.45 | -2.52 | 1,12,922.46 | 22.95 | 3.87 | 0.87 | 0.81 |
| Torrent Pharmaceuticals | Bullish | 4,018.75 | 0.35 | 1,36,007.30 | 67.32 | 17.1 | 0.83 | 17.62 |
| Dr Reddy's Laboratories | Bearish | 1,175.65 | -0.91 | 98,110.38 | 18.63 | 3.14 | 0.63 | 2.34 |
| Sun Pharmaceutical Industries | Bearish | 1,669.20 | -1.84 | 4,00,487.56 | 36.24 | 5.77 | 0.92 | 0.50 |
| Divi's Laboratories | Bearish | 6,233.95 | -1.93 | 1,65,491.79 | 78.61 | 11.52 | 0.46 | 0.01 |
| Meeting Date | Purpose |
|---|---|
| 2026-02-12 | Quarterly Results |
| 2025-11-12 | Quarterly Results |
| 2025-05-28 | Audited Results |
| 2025-02-12 | Quarterly Results |
| 2024-11-12 | Quarterly Results |
Cohance Lifesciences is trading at 425.65 as on Fri Jan 16 2026 10:24:28. This is -3.58% lower as compared to its previous closing price of 441.45.
The market capitalization of Cohance Lifesciences is 16283.97 Cr as on Fri Jan 16 2026 10:24:28.
The average broker rating on Cohance Lifesciences is Buy. The breakup of analyst rating is given below -
The 52 wk high for Cohance Lifesciences is 1328.20 whereas the 52 wk low is 439.25
Cohance Lifesciences can be analyzed on the following key metrics -
Cohance Lifesciences reported a net profit of 267.87 Cr in 2025.
The Mutual Fund Shareholding was 16.49% at the end of 30 Sep 2025.
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.